title: [New therapeutic strategies for community acquired pneumonia].
abstract: Community Acquired Pneumonia (CAP) is the most important infectious disease in Germany. In the acute phase, lethality is almost 10%, and in the six months follow up period following the acute infection, lethality is more than 15%. Problems with resistances had not been found in Germany, except for a decreasing susceptibility of S. pneumoniae against macrolides. The CRB-65 score allows a reliable discrimination between patients with a high and low risk of dying. The new S3 guideline for diagnosis and treatment of community acquired pneumonia recommends a risk adapted treatment. Low risk patients shall receive a monotherapy with e. g. amoxicillin, high risk patients should be treated with a broad spectrum combination therapy (beta-lactam and macrolide).
authors.affiliation: Abteilung Pneumologie, Medizinische Hochschule Hannover.
authors.forename: T
authors.initials: T
authors.lastname: Welte
authors.forename: R
authors.initials: R
authors.lastname: Marre
authors.forename: N
authors.initials: N
authors.lastname: Suttorp
mesh_terms: D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D017714:Community-Acquired Infections / Q000175:diagnosis / Q000188:drug therapy / Q000401:mortality; D005858:Germany / Q000453:epidemiology; D006801:Humans; D011014:Pneumonia / Q000175:diagnosis / Q000188:drug therapy* / Q000401:mortality*; D017410:Practice Guidelines as Topic; D010818:Practice Patterns, Physicians'; D016896:Treatment Outcome
chemical_list: D000900:Anti-Bacterial Agents